Quince Therapeutics, Inc.
QNCXNasdaq
$18.88
↑ +1.1%Jul 17 close · end-of-day
Price
1Y↓ -94.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$173.5M
Enterprise Value
$155.4M
P/E
4.1
P/S
—
P/B
11.1
EV/EBITDA
—
PEG
—
FCF Yield
-22.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$33.0M
Free Cash Flow (TTM)
-$39.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-210.8%
ROIC
—
Debt / Equity
0.0
Net Cash
$18.2M
Return 1Y
-94.8%
Company profile
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.
- CEO
- Dirk Thye
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- California
- Website
- quincetx.com
Management & directors
- Thye DirkCEO and CMO
- Hannah BrendanCBO, COO & CCO
- Ryan Charles S.President
Roles derived from SEC Form 4 filings.
Earnings
QNCX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS$2.88↓ -184.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$78.9M | -$90.3M | -$52.0M | -$34.6M | -$57.3M | -$58.1M |
| Net income | -$76.8M | -$89.9M | -$51.7M | -$31.4M | -$56.8M | -$84.0M |
| Diluted EPS | — | -$3.03 | -$1.54 | -$0.84 | -$1.31 | -$1.68 |
| Operating cash flow | -$50.8M | -$62.9M | -$44.0M | -$18.3M | -$31.9M | -$41.4M |
| Free cash flow | -$50.9M | -$63.1M | -$44.2M | -$18.5M | -$32.2M | -$41.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$28.2M | -$5.9M | -$12.0M | -$14.9M | -$10.4M | -$13.4M | -$19.4M | -$14.6M |
| Net income | -$27.7M | -$5.5M | -$12.5M | -$15.0M | -$16.0M | -$13.4M | -$39.5M | $35.9M |
| Diluted EPS | -$0.64 | -$0.13 | -$0.28 | -$3.42 | -$0.34 | -$0.25 | $2.33 | $2.88 |
| Operating cash flow | -$8.7M | -$7.3M | -$7.6M | -$9.6M | -$11.4M | -$9.9M | -$10.5M | -$7.6M |
| Free cash flow | -$8.8M | -$7.3M | -$7.7M | -$9.7M | -$11.5M | -$10.0M | -$10.5M | -$7.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 18, 2026
- 63d agoUPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDfinance.yahoo.com
- 63d agoQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipelinefinance.yahoo.com
- 63d agoQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDfinance.yahoo.com
Mar 30, 2026
Mar 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-26 | Benatti Luca | Sale | 50,000 | $3.47 | $173,500.00 | filing |
| 2025-12-10 | Thye Dirk· CEO and CMO | Gift | 739,885 | $0.00 | $0.00 | filing |
| 2025-12-10 | Thye Dirk· CEO and CMO | Gift | 739,885 | $0.00 | $0.00 | filing |
| 2025-12-05 | Hannah Brendan· CBO, COO & CCO | Option exercise | 25,280 | $0.94 | $23,763.20 | filing |
| 2025-12-05 | Hannah Brendan· CBO, COO & CCO | Option exercise | 2,271 | $0.55 | $1,249.05 | filing |
| 2025-06-18 | Thye Dirk· CEO and CMO | Award | 150,944 | $1.20 | $181,132.80 | filing |
| 2025-06-18 | Hannah Brendan· CBO, COO & CCO | Award | 37,736 | $1.20 | $45,283.20 | filing |
| 2025-06-18 | Ryan Charles S.· President | Award | 7,548 | $1.20 | $9,057.60 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.